Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Skin Cancer Channel is supported with funding from Iovance Biotherapeutics (Silver).

VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.

Share this video  

ASCO 2024 | MelaRisk-001: validation of a 7-marker IHC assay in stage IB/IIA cutaneous melanoma

Teresa Amaral, MD, PhD, University of Tübingen, Tübingen, Germany, discusses the multicenter MelaRisk-001 study (NCT05933577), which assessed a prognostic 7-marker immunohistochemistry (7-IHC) assay for stage IB/IIA cutaneous melanoma (CM). This study aims to identify high or low recurrence risk in patients using primary tumor assays involving immunohistochemistry (IHC) and gene expression profiling. These assays could be used with or without sentinel lymph node biopsy data. This is crucial as current adjuvant treatments are given without specific biomarkers, risking unnecessary toxicity and costs. This interview took place during the 2024 American Society of Clinical Oncology (ASCO) Meeting in Chicago, IL.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Disclosures

Consulting or Advisory Role – CeCaVa; Delcath Systems; NeraCare GmbH; Novartis; Pierre Fabre
Research Funding – Agenus (Inst); AstraZeneca (Inst); BioNTech SE (Inst); Biotech IOB (Inst); BMS GmbH & Co. KG (Inst); HUYA Bioscience International (Inst); Immunocore (Inst); MSD (Inst); NeraCare GmbH (Inst); Novartis (Inst); Pfizer (Inst); Philogen (Inst); Regeneron (Inst); Replimune (Inst); Roche/Genentech (Inst); Sanofi Aventis GmbH (Inst); Skyline Diagnostics (Inst)

Choose your cookie settings

VJOncology uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.